Oppenheimer Increases Alimera Sciences PT
Oppenheimer increased its Alimera Sciences (NASDAQ: ALIM) price target from $4 to $7 in a research report published today.
In the report, Oppenheimer stated, "We believe ALIM is leaning toward a commercialization partnership, which would bring in needed capital near-term. We believe ALIM is substantially undervalued on Iluvien's E.U. opportunity."
Shares of Alimera Sciences closed today at $3.94, up 70.56% from Monday's market close.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.